TM Owner Regeneron
Libtayo 350mg Vial
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Libtayo 350mg is a concentrate for solution for infusion containing cemiplimab, a programmed death receptor-1 (PD-1) blocking monoclonal antibody that helps the immune system recognise and attack cancer cells.
- A healthcare professional gives it as an intravenous infusion over 30 minutes in hospital or a specialist clinic.
- Libtayo treats adults with metastatic or locally advanced cutaneous squamous cell carcinoma who cannot have curative surgery or radiation, and is also used after surgery and radiation in high-risk cutaneous squamous cell carcinoma; locally advanced or metastatic basal cell carcinoma after a hedgehog pathway inhibitor or when one is unsuitable; and non-small cell lung cancer, either alone when PD-L1 expression is high (TPS 50% or more) or with platinum chemotherapy, in tumours without EGFR, ALK or ROS1 changes.
- In the European Union it is additionally approved for recurrent or metastatic cervical cancer after platinum chemotherapy.
Side Effects
- The most common side effects with Libtayo given alone affect more than 1 in 10 people and include tiredness (38%), rash (34%), muscle and bone pain (33%), diarrhoea (26%) and anaemia (14%); when it is combined with chemotherapy, hair loss (37%), nausea, numbness or tingling and reduced appetite are also frequent.
- Libtayo has NO boxed warning.
- Its most important risks are immune-mediated reactions, which can be severe or fatal and may affect any organ: pneumonitis (2.6%), hepatitis (2.4%), colitis (2%), nephritis, thyroid and other hormone gland problems, myocarditis and serious skin reactions including Stevens-Johnson syndrome.
- Severe or life-threatening infusion-related reactions occurred in 0.2% of patients, and fatal complications of allogeneic stem cell transplantation have been reported.
- Tell your care team promptly about new cough or breathlessness, persistent diarrhoea, yellowing of the skin, severe rash, chest pain or unusual tiredness.
Precautions & Warnings
- Libtayo is a specialist hospital medicine given only under the supervision of a clinician experienced in cancer immunotherapy.
- Immune-mediated reactions may begin during treatment or weeks to months after the last dose, so monitoring of liver enzymes, kidney function, thyroid and other hormone levels and blood counts continues after therapy ends; treatment is withheld or permanently stopped and corticosteroids started depending on severity.
- Tell your care team if you have an autoimmune disease, have had a solid organ transplant, or have had or are planning an allogeneic stem cell transplant, because fatal graft-versus-host disease and hepatic veno-occlusive disease have occurred.
- Cemiplimab can harm an unborn baby, so pregnancy should be excluded and effective contraception used during treatment and for 4 months after the last dose; do not breastfeed during this period.
- The 350 mg/7 mL vial is diluted before use and infused over 30 minutes through a line with a sterile filter, never as a rapid bolus.
Avoid Interactions
- No formal drug interaction studies are included in the Libtayo prescribing information, and cemiplimab is a monoclonal antibody that is not metabolised by liver enzymes, so the usual interactions with grapefruit or with CYP3A4 inhibitors and inducers are not expected.
- The main concern is with medicines that blunt the immune response: systemic corticosteroids or other immunosuppressants taken before treatment starts may reduce how well Libtayo works, although corticosteroids are the correct treatment once an immune-mediated side effect appears.
- Live vaccines are generally avoided during checkpoint inhibitor therapy, so discuss the timing of any vaccination with your care team.
- Tell your healthcare provider about every prescription medicine, over-the-counter product, herbal remedy and supplement you take, including steroids used for other conditions.
- At pharmacy level, Libtayo is diluted only in 0.9% sodium chloride or 5% dextrose, must not be mixed with or infused through the same line as other medicines, and must not be shaken or frozen.
References
Frequently Asked Questions
Libtayo (cemiplimab) is a PD-1 blocking immunotherapy for adults with advanced cutaneous squamous cell carcinoma, advanced basal cell carcinoma after a hedgehog pathway inhibitor, and non-small cell lung cancer. In the European Union it is also approved for recurrent or metastatic cervical cancer after platinum chemotherapy.
Libtayo 350mg is given as a drip into a vein over 30 minutes, usually once every 3 weeks, by a healthcare professional in hospital. In the adjuvant skin cancer setting the schedule can change to 700 mg every 6 weeks. Treatment continues until the cancer progresses or side effects become unacceptable.
The most common side effects of Libtayo (cemiplimab) are tiredness, rash, muscle and bone pain, diarrhoea and anaemia. Immune-mediated reactions can be severe or fatal and may affect the lungs, bowel, liver, kidneys, hormone glands, heart or skin. Report new cough, breathlessness, persistent diarrhoea, yellow skin or severe rash straight away.
Avoid live vaccines during Libtayo treatment, and tell your care team before taking steroids or other immune-suppressing medicines, because these may reduce how well cemiplimab works. Avoid pregnancy: use effective contraception during treatment and for 4 months after the last dose, and do not breastfeed.
The 350 mg vial is diluted and given through a drip over about 30 minutes; it is never injected as a rapid bolus. Nurses watch for infusion reactions such as fever, chills, flushing or breathlessness, which were severe in 0.2% of patients. Blood tests are done before each cycle.
No. Libtayo (cemiplimab) has no boxed warning in its US prescribing information. Its most serious risks are immune-mediated reactions that can affect any organ and may start weeks or months after the last dose, so blood counts and liver, kidney and thyroid tests continue after treatment ends.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
